Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fib ...

Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE ...

Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and ...

Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal comp ...

A Sarasota biopharmaceutical company is applying for a patent for an Alzheimer’s drug. Silo Pharma, based on North Washington ...

Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel ...

H.C. Wainwright & Co. is acting as manager. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart ...

Back when Nvidia was a scrappy startup, CEO Jensen Huang enforced one rule: Work at the speed of light—let physics, never bureaucracy, be your only limit. He wasn’t joking. Take Nvidia’s first ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MANILA, Philippines – The head of a local group of pharmaceutical firms has expressed confidence that US President Donald Trump’s new tariff policy will have minimal impact on their sector ...